Electromedical Technologies, Inc. (OTCQB: EMED) is engaged as a commercial-stage bioelectronic medical device company, which is focused on developing treatments for a variety of pain conditions. Shares of the medical device company are rallying 29% through early trading on Tuesday, November 1, 2022. Over the past thirty days, Electromedical Technologies has seen average daily volume of 1.19 million shares. However, volume of 2.59 million shares or dollar volume of around $34,706, has already exchanged hands through early trading.
Shares of Electromedical Technologies are gaining after the company introduced its next-generation medical device, the WellnessPro Infinity. The new device seeks to represent a new standard in the bioelectronics marketplace.
The WellnessPro Infinity is a compact device that is capable of producing all electrotherapy modalities. This means the device is able to produce any frequency, any wave form (typical or atypical) and any level of modulation. Furthermore, the device is designed to support a variety of different use-cases: TENS, microcurrent, IF, EMS, PEMF, CES, VNS, PNS, Cold Laser, POD Synchronization, IDNA, Deep Pluse, Cloud and more.
Management says the WellnessPro Infinity is extremely accurate and among the easiest electrotherapy devices available on the market. The next-gen device also features a doctor-patient portal, which allows medical professionals to update and personalize treatments.
Electromedical Founder and CEO, Matthew Wolfson: ” I want to thank our shareholders for the continued support, everyone at EMED and especially our incredible engineering team in Europe, for the hard work, innovation and long hours our team put in, to create a device we believe will help millions of people live happier healthier Pain Free lives and help battle the Opioid epidemic. Now that we have completed development of our NEW flagship model by October as planned, the next step is electrical laboratory safety testing. After that, it will be production ready. Once production is underway, we will begin taking pre orders. Our goal is to start shipping units next quarter. POD development is going as planned and we look forward to sharing progress in our upcoming press releases soon. Our goal is to go to market with the WellnessPro Infinity™ first, then shortly after releasing the POD upon FDA 510k clearance.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
